Výsledky vyhledávání - "Narayana Narasimhan"

Akademický článek

Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach

Autor: Michael J. Hanley, Karen Rowland Yeo, Meera Tugnait, Shinji Iwasaki, Narayana Narasimhan, Pingkuan Zhang, Karthik Venkatakrishnan, Neeraj Gupta

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 4, Pp 624-637 (2024)

Abstract Brigatinib is an oral anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of ALK‐positive metastatic non‐small cell lung cancer. In vitro studies indicated that brigatinib is primarily metabolized by CYP2C8 and CYP3A4 a

Externí odkaz: https://doaj.org/article/f60485c9b0764388b669749419b519e4

Zobrazit plný text záznamu

Plný text ve formátu HTML

Data from The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models

Purpose: Non–small cell lung cancers (NSCLCs) harboring ALK gene rearrangements (ALK+) typically become resistant to the first-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) crizotinib through development of secondary r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5126f7a2057f9c47635f6496d280ebf0
https://doi.org/10.1158/1078-0432.c.6525524.v1

Zobrazit plný text záznamu

Supplementary Methods, Supplementary Results, Supplementary Table 1, Supplementary Figures 1-8 from The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models

Supplementary Table 1. Brigatinib in vitro activity (IC50s) in a kinase panel (N=289); Supplementary Figure 1. Chemical structures of brigatinib, crizotinib, ceritinib, and alectinib; Supplementary Figure 2. Brigatinib-mediated inhibition of native o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c6bdb6961073a5b3e650ddfb94203a6
https://doi.org/10.1158/1078-0432.22463789.v1

Zobrazit plný text záznamu

Abstract 3342: Discovery of potent and selective next-generation EGFR inhibitors with activity against single, double, and triple mutant EGFR variants including T790M and C797S

Autor: Wei-Sheng Huang, Sara Nadworny, Narayana Narasimhan, Charles J. Eyermann, David C. Dalgarno, Victor M. Rivera, William C. Shakespeare

Publikováno v: Cancer Research. 82:3342-3342

Introduction: EGFR activating mutations are observed in 10-50% of NSCLC patients and the common mutations (L858R [L] and exon 19 deletions [D]) are initially sensitive to first-, second-, and third-generation EGFR inhibitors (eg erlotinib [1G], afati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3b478b2d980afa91a4eec642fa30c3f7
https://doi.org/10.1158/1538-7445.am2022-3342

Zobrazit plný text záznamu

Lack of meaningful effect of ridaforolimus on the pharmacokinetics of midazolam in cancer patients: model prediction and clinical confirmation

Autor: Mark, Stroh, Jennifer, Talaty, Punam, Sandhu, Jacqueline, McCrea, Amita, Patnaik, Anthony, Tolcher, John, Palcza, Keith, Orford, Sheila, Breidinger, Narayana, Narasimhan, Deborah, Panebianco, Richard, Lush, Kyriakos P, Papadopoulos, John A, Wagner, Michele, Trucksis, Nancy, Agrawal

Publikováno v: Journal of clinical pharmacology. 54(11)

Ridaforolimus, a unique non-prodrug analog of rapamycin, is a potent inhibitor of mTOR under development for cancer treatment. In vitro data suggest ridaforolimus is a reversible and time-dependent inhibitor of CYP3A. A model-based evaluation suggest

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e637abbd9be4c5f0f8cea12b7349cceb
https://pubmed.ncbi.nlm.nih.gov/24827931

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání